Welcome to our dedicated page for QUANTUM X LABS SEC filings (Ticker: QXL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quantum X Labs Inc. (QXL) SEC filings document the regulatory history of a Nasdaq-listed company formerly known as Viewbix Inc. The company’s 10-Q reports include consolidated financial statements prepared under U.S. GAAP, notes on wholly owned subsidiaries, business combination accounting, and acquisition-related disclosures involving Quantum X Labs Ltd. and Metagramm.
For QXL, quarterly reports and annual reports are important because the company’s identity combines several disclosed operating areas: quantum technology, digital advertising, computing, and enterprise AI solutions. Investors reviewing QXL 10-Q and 10-K filings can examine how the company presents consolidated subsidiaries, goodwill and intangible assets, business combinations, and technology-related disclosures tied to its operating structure.
Current reports on Form 8-K are also relevant for Quantum X Labs because the company has used them to report material events, including the acquisition of Quantum X Labs Ltd., pro forma financial information, officer appointments, and technology announcements related to neutral-atom quantum computing. Form 4 filings, when present, show insider transactions, while proxy materials can provide details on governance and compensation matters.
AI-powered summaries can make QXL filings easier to read by translating 10-Q, 10-K, 8-K, and Form 4 disclosures into plain-language explanations. Real-time EDGAR updates, simplified filing highlights, quarterly report summaries, annual report explanations, and insider transaction access are especially useful for a company whose filings connect acquisition history, software subsidiaries, and technical quantum programs.
QUANTUM X LABS INC. (QXL) reports that Co-CEO Yakov Baranes purchased 5,000 shares of common stock on September 15, 2026 in an open-market transaction at a weighted average price of $4.88 per share, with individual trade prices ranging from $4.88 to $4.97. Following this purchase, he directly owns 358,177 common shares. No transactions are reported as made under a Rule 10b5-1 trading plan.
Quantum X Labs Inc. (QXL) reported that on September 15, 2026 it appointed Yossi Cohen, former Director of the Mossad and former National Security Advisor of Israel, as President of its Scientific Advisory Board.
Cohen will work with existing board members to guide Quantum X Labs’ strategy in quantum computing, quantum error correction, quantum cybersecurity, quantum sensing, GPS-denied navigation and precision timing, with a focus on defense, aerospace, homeland security and critical infrastructure applications. The company highlights that Cohen’s current role as a strategic advisor to SoftBank and his 38-year national security career are expected to support its efforts to commercialize quantum technologies and develop international and government-focused partnerships.
QUANTUM X LABS INC. (QXL) director Yoresh Eliyahu, through Yoresh Capital Ltd., reported an open-market purchase of 4,500 shares of common stock on August 21, 2026 at a weighted average price of $4.77 per share, with trade prices ranging from $4.70 to $4.88. Following this transaction, Yoresh Capital Ltd. held 7,018 shares indirectly attributed to Eliyahu subject to a disclaimer of beneficial ownership except for his pecuniary interest. A separate line reports 435,951 shares held directly, with a footnote stating that no transaction occurred for those shares and they are included for informational purposes only.
Quantum X Labs Inc. (QXL) received an amended Schedule 13G filing reporting beneficial ownership by Nissim Daniel and J.B.D Innovation Ltd. Based on 21,817,826 common shares outstanding, Mr. Daniel is reported with beneficial ownership of 7.61% and J.B.D Innovation Ltd. with 5.90%.
Mr. Daniel’s beneficial position consists of 350,271 shares held directly and 44,283 shares issuable within 60 days under a pre-funded warrant, subject to a 4.99% blocker. J.B.D Innovation Ltd.’s position includes 300,000 shares held, plus 750,000 option shares and 300,000 warrant shares exercisable within 60 days, also subject to a 4.99% blocker. Mr. Daniel, as sole owner and director of J.B.D Innovation Ltd., may be deemed to share beneficial ownership, while each reporting person disclaims beneficial ownership beyond its pecuniary interest.
Quantum X Labs Inc. (QXL) received an updated ownership report from Israeli investors L.I.A. Pure Capital Ltd. and Xylo Technologies Ltd. The Reporting Persons together beneficially own 2,179,600 shares of common stock, representing 9.99% of the outstanding 21,817,826 shares, based on information provided by the company. This position includes 1,727,817 shares held by L.I.A. Pure Capital, 315,066 shares held by Xylo, and 136,717 shares that L.I.A. Pure Capital may acquire within 60 days through warrant exercise, all subject to blocker provisions. Additional pre-funded and regular warrants held by L.I.A. Pure Capital, totaling potential acquisition of 1,742,998 shares, are excluded from the reported beneficial ownership because 4.99% ownership caps limit when they can be exercised.
Quantum X Labs Inc. (QXL) reported interim results for the six months ended June 30, 2026, reflecting a major portfolio shift toward quantum technology and AI while its legacy digital advertising business contracts. Total assets rose to $31.2 million from $10.8 million, driven mainly by the March 2026 acquisition of Quantum X Labs Ltd. (Quantum Israel), which added goodwill of $14.3 million and in‑process R&D of $0.5 million.
From continuing operations, revenue declined to $646 thousand from $899 thousand, and the operating loss widened to $1.9 million from $1.1 million as general and administrative and R&D expenses increased. Despite this, QXL posted net income attributable to shareholders of $1.9 million, versus a $15.3 million loss a year earlier, mainly due to a $3.8 million gain on deconsolidation of CliniQuantum and the absence of prior‑year fair‑value losses on derivatives and discontinued operations.
Cash and cash equivalents improved to $2.4 million from $1.0 million, supported by a $1.4 million March 2026 private placement and $2.4 million of warrant exercises, offset by continued operating cash outflows. The company highlights a going‑concern uncertainty due to declining search‑segment revenues, past impairments and limited liquidity, despite recent financings and cost‑cutting measures. The Cortex digital content business was sold in 2025 and is presented as discontinued operations. Management also notes regional geopolitical risks around Israel but reports that customers are mainly in the U.S. and Europe.
Quantum X Labs Inc. director Yoresh Eliyahu exercised a pre-funded warrant to acquire 88,675 shares of common stock. The warrant had a stated exercise price of $0.0001 per share and was exercised on a cashless basis, so no shares were withheld for taxes or payment.
After the exercise, Eliyahu held 435,951 shares of Quantum X Labs common stock directly and 2,518 shares indirectly through Yoresh Capital Ltd. The filing shows an exercise-and-hold pattern, with no open-market sales reported in this transaction.
QUANTUM X LABS INC. Co-CEO Baranes Yakov exercised a pre-funded warrant to acquire 246,387 shares of common stock on May 31, 2026. The shares were obtained at an exercise price of $0.0001 per share on a cashless basis, and no shares were withheld for taxes or fees.
Following the exercise, his directly held common stock position increased to 353,177 shares. The corresponding pre-funded warrant for 246,387 underlying shares was fully exercised and now shows zero remaining derivative balance.
QUANTUM X LABS INC. director Ronen Rosenbloom filed an initial Form 3, which is the required statement of beneficial ownership when an insider first becomes subject to reporting rules. This filing lists him as a director but does not report any share transactions or derivative positions.
QUANTUM X LABS INC. reported that Tzedef Kineret filed an initial Form 3 as a director of the company. This filing is a required ownership disclosure for new insiders and does not show any stock purchases, sales, option exercises, or other transactions.